Statistical analyses were performed by a study biostatistician (D.A.L.), and were independently confirmed by a biostatistician not affiliated with the study (M.P.). compared to placebo around the CAPS hyperarousal symptom cluster.GR205171was well-tolerated, with no discontinuations due to adverse events. CSF SP concentrations were positively correlated with baseline CAPS severity. The selective NK1R antagonistGR205171had fewer adverse effects but was not significantly superior to placebo in the short-term treatment Cefotaxime sodium of chronic PTSD. (ClinicalTrials.govIdentifier: NCT 00211861,NCT 00383786) Keywords:NK1, material P, PTSD, clinical trial, randomized == INTRODUCTION == Despite the enormous societal impact of posttraumatic stress disorder (PTSD), few pharmacotherapies are associated with consistently robust improvements in all three symptom domains (i.e., reexperiencing, avoidance/emotional numbing, and hyperarousal). U.S. practice guidelines have endorsed cognitive-behavioral therapy (CBT) and selective serotonin reuptake inhibitors Cefotaxime sodium (SSRIs) as first-line treatments (Benedek et al., 2004). However, the only two U.S. Food and Drug Administration (FDA)-approved medications, sertraline and paroxetine, have modest effect sizes (Stein et al., 2006), and a minority of patients in short-term clinical trials achieve remission (Mathew et al., 2009). Moreover, SSRI medication may provide limited benefit in subgroups of PTSD patients such as combat veterans (Benedek et al., 2004;Friedman et al., 2008). In light of these findings, coupled with substantial evidence for the efficacy of exposure-based psychotherapies, recent influential Kit reports have recommended that pharmacotherapy should not be routinely used as a first-line treatment for PTSD due to lack of sufficient evidence for efficacy (National Institute for Clinical Excellence (NICE), 2005;Committee on Treatment of Posttraumatic Stress Disorder (Institute of Medicine), 2007). Thus, it is imperative to identify novel therapies that improve upon and are mechanistically distinct from existing pharmacological treatments. The neurotransmitter material P (SP) together with its preferred neurokinin1receptor (NK1R) may serve important roles in the modulation of stress and anxiety (Ebner and Singewald, 2006). NK1R are broadly distributed in neural regions implicated in stress responsivity, including the hypothalamus, basolateral amygdala, hippocampus, nucleus accumbens, and frontal cortex (Gobert et al., 2009;Hietala et al., 2005;Nakaya et al., 1994). In preclinical experiments, immobilization stress induced activation of NK1R by SP in the amygdala was associated with increased anxiety-like behavior (Ebner et al., 2004), whereas pharmacological or genetic inactivation of NK1R inhibited the associated behavioral responses in several models (George et al., 2008;Holmes et al., 2003;Varty et al., 2002;Santarelli et al., 2001). Few clinical studies have investigated the SP-NK1R system in stress-related stress disorders. Significant elevations in SP concentrations in cerebrospinal fluid (CSF) were found in male combat veterans with PTSD, as well as phasic Cefotaxime sodium increases in SP following symptom-provocation (Geracioti et al., 2006). Patients with panic disorder studied with positron emission tomography and [18F]SPA-RQ showed widespread reduction (12-21%) of NK1R binding in multiple brain regions, potentially consistent with repeated release of SP (Fujimura et al., 2009). Fear provocation in phobic patients was associated with reduced NK1R availability in the amygdala, indicating increased release of endogenous SP (Michelgard et al., 2007). A pharmaco-fMRI study with the NK1R antagonistLY686017found reductions in BOLD response to aversive images Cefotaxime sodium in two brain regions (inferior frontal cortex and insula) relevant to stress and reward regulation (George et al., 2008). Finally, the selective NK1R antagonistGR205171reduced state stress, distress, and heart rate during a stressful public speaking task, and attenuated amygdala responses to social Cefotaxime sodium threats in patients with social phobia (Furmark et al., 2005). In this proof-of-concept, 8-week, randomized, double-blind, placebo-controlled trial, we.